文献速递肝病

索磷布韦/维帕他韦/伏西瑞韦在既往接受索磷布韦/维帕他韦或格卡瑞韦/哌仑他韦治疗的丙型肝炎患者中的真实世界有效性

Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir.
PubMed 文献 · Aliment Pharmacol Ther · 2024-05-02

这项回顾性多中心研究纳入142例既往索磷布韦/维帕他韦或格卡瑞韦/哌仑他韦治疗失败的慢性丙型肝炎患者,接受索磷布韦/维帕他韦/伏西瑞韦±利巴韦林12周。132例可评估患者中117例(88.6%)获得持续病毒学应答,不同初始治疗、肝硬化状态及基因3型感染间无显著差异。

要点

  • 索磷布韦/维帕他韦/伏西瑞韦挽救治疗总体持续病毒学应答率为88.6%。
  • 初始方案为索磷布韦/维帕他韦者持续病毒学应答率87.9%,格卡瑞韦/哌仑他韦者90.2%,无显著差异。
  • 无肝硬化者持续病毒学应答率90%,肝硬化者87.1%,无显著差异。

核心结论

  • 索磷布韦/维帕他韦/伏西瑞韦是索磷布韦/维帕他韦或格卡瑞韦/哌仑他韦治疗失败后有效的挽救治疗,持续病毒学应答率为88.6%。
  • 既往与较低持续病毒学应答率相关的因素如基因3型感染、肝硬化和一线索磷布韦/维帕他韦治疗未与较低持续病毒学应答率相关。

研究设计与样本

  • 回顾性多中心研究,纳入26家西班牙医院中索磷布韦/维帕他韦或格卡瑞韦/哌仑他韦治疗失败后接受索磷布韦/维帕他韦/伏西瑞韦±利巴韦林12周治疗的慢性丙型肝炎患者。
  • 共纳入142例患者,其中100例(70.4%)既往索磷布韦/维帕他韦治疗失败,42例(29.6%)格卡瑞韦/哌仑他韦治疗失败;患者主要为男性(84.5%)、白人(93.9%),丙型肝炎病毒基因3型占49.6%,47.2%有肝硬化。
  • 治疗时间为2017年12月至2022年12月。
  • 持续病毒学应答在完成索磷布韦/维帕他韦/伏西瑞韦治疗并随访至治疗结束后12周的132例患者中评估。

主要发现

  • 132例可评估患者中117例(88.6%)获得持续病毒学应答。
  • 根据初始直接抗病毒药物治疗,持续病毒学应答率无显著差异:索磷布韦/维帕他韦组87.9% vs 格卡瑞韦/哌仑他韦组90.2%,p=0.8。
  • 根据肝硬化状态,持续病毒学应答率无显著差异:无肝硬化组90% vs 肝硬化组87.1%,p=0.6。
  • 根据基因3型感染,持续病毒学应答率无显著差异:非基因3型组91.9% vs 基因3型组85.5%,p=0.3。
  • 当同时考虑索磷布韦/维帕他韦治疗、肝硬化和基因3型感染时,持续病毒学应答率降至82.8%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Sofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX) is the recommended rescue therapy for patients with chronic hepatitis C infection who fail direct-acting antivirals (DAAs). Data are limited on the effectiveness of this treatment after the current first-line therapies. Our aim was to analyse the effectiveness and safety of SOF/VEL/VOX among patients failing sofosbuvir/velpatasvir (SOF/VEL) or glecaprevir/pibrentasvir (GLE/PIB). METHODS: Retrospective multicentre study (26 Spanish hospitals), including chronic hepatitis C patients unsuccessfully treated with SOF/VEL or GLE/PIB, and retreated with SOF/VEL/VOX ± ribavirin for 12 weeks between December 2017 and December 2022. RESULTS: In total, 142 patients included: 100 (70.4%) had failed SOF/VEL and 42 (29.6%) GLE/PIB. Patients were mainly men (84.5%), White (93.9%), with hepatitis C virus genotype (GT) 3 (49.6%) and 47.2% had liver cirrhosis. Sustained virological response (SVR) was evaluated in 132 patients who completed SOF/VEL/VOX and were followed 12 weeks after end of treatment; 117 (88.6%) achieved SVR. There were no significant differences in SVR rates according to initial DAA treatment (SOF/VEL 87.9% vs. GLE/PIB 90.2%, p = 0.8), cirrhosis (no cirrhosis 90% vs. cirrhosis 87.1%, p = 0.6) or GT3 infection (non-GT3 91.9% vs. GT3 85.5%, p = 0.3). However, when considering the concurrent presence of SOF/VEL treatment, cirrhosis and GT3 infection, SVR rates dropped to 82.8%. Ribavirin was added in 8 (6%) patients, all achieved SVR. CONCLUSION: SOF/VEL/VOX is an effective rescue therapy for failures to SOF/VEL or GLE/PIB, with an SVR of 88.6%. Factors previously linked to lower SVR rates, such as GT3 infection, cirrhosis and first-line therapy with SOF/VEL were not associated with lower SVRs.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Ruiz-Cobo JC, Llaneras J, Forns X, et al. Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir. Aliment Pharmacol Ther. 2024. PMID: 38695095. doi:10.1111/apt.18020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。